Title: No association between having a pregnancy complicated by vaginal bleeding and long-

term risk of cancer

Elena Dudukina,[1] Erzsébet Horváth-Puhó,[1] Henrik Toft Sørensen,[1] Vera Ehrenstein[1]

[1]Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus,

Denmark

Corresponding author:

Elena Dudukina

Olof Palmes Alle 43-45

8200

Aarhus N

Email: e.dudukina@clin.au.dk

ORCID identifier: 0000-0002-4238-049X

ABSTRACT (MAX 200)

Background: A full-term pregnancy is associated with a reduction in risks of breast, endometrial, and ovarian cancer. The long-term risk of cancer in women with vaginal bleeding in pregnancy is unknown.

Methods: This was a registry-based cohort study (1995-2017) conducted in Denmark. We included pregnancies (37 061) affected by vaginal bleeding (VB) within 20 gestational weeks among 35 495 women, VB-unaffected pregnancies (1 362 783) among 783 041 women, pregnancies ending in a termination (324 234) among 239 568 women or miscarriage (136 974) among 121 239 women. We computed absolute risk of cancer and hazard ratios (HR) with 95% confidence intervals (CIs) adjusted for age, calendar year, reproductive history, history of chronic conditions, medication use, and socioeconomic factors using Cox proportional hazards regression.

Results: The absolute risk of any cancer was 9.8% following VB-affected pregnancy and 9.9% following VB-unaffected pregnancy, 9.3% following a termination and 10.3% following a miscarriage. We found no association between VB and any cancer in comparison with VB-unaffected pregnancies (HR: 1.02, 95% CI: 0.97-1.07), terminations (HR: 1.05, 95% CI: 1.00-1.11) or miscarriages (HR: 0.94, 95% CI: 0.88-0.98).

Conclusions: A VB-affected pregnancy ending in a childbirth was not associated with increased risk of cancer in women.

Abstract word count: 200

Word count: 2782

INTRODUCTION

Gestation is sustained with progesterone that may play a protective role for hormone-related cancers,

such as endometrial and breast cancer (1,2). Threatened and completed miscarriage share several

biologic mechanisms, including increased levels of pro-inflammatory cytokines (3–5) and decreased

levels of progesterone (6,7). Threatened miscarriage affects up to 30% (8–12) of clinically identified

pregnancies and manifests as vaginal bleeding (VB), often during the first trimester (8,9,13). About

30-50% (6,14,15) of VB-affected pregnancies end in a miscarriage (16–18).

A full-term pregnancy is associated with a 40% reduction in risks of breast, endometrial, and ovarian

cancer (19,20). A pregnancy irrespective of outcome is associated with a reduction in risks of

endometrial, breast, and ovarian cancers (1,2,19). However, pregnancy ending in a miscarriage is

associated with a less pronounced protective effect against cancer of 10% (1).

The long-term risk of cancer in women with a pregnancy complicated by vaginal bleeding within 20

gestational weeks is unknown. A previous Danish study showed that VB in pregnancy is not a marker

of occult cancer (21). In this registry-based cohort study in Denmark, we investigated an association

between having a VB-affected pregnancy ending in childbirth with the subsequent risk of cancer as

compared with having an VB-unaffected pregnancy ending in childbirth, pregnancy ending in a

termination or miscarriage.

METHODS

Setting, design and data sources

This was a registry-based cohort study conducted using patient-level linked data from Danish health

and administrative registries (22), set within Denmark's universal and tax-funded health care system.

The Civil Registration System (22,23) assigns personal identifiers and contains data on date of birth,

vital and civil status, dates of immigration and emigration. Data on all deliveries are captured by the

Medical Birth Registries (MBR) starting in 1973 (24,25) and includes women's and pregnancy-related

characteristics including but not limited to women's age at delivery, gestational age, and parity.

Smoking status in pregnancy is collected by the MBR from 1991 and body-mass index (BMI) from

2004. Information on stillbirths at the gestational age of at least 28 full weeks is available in the MBR

before April 2004 and at 22 full gestational weeks afterwards; livebirths are recorded regardless of

gestational age. Information on highest education level (26), employment status (27) and personal

income (28) are stored at Statistics Denmark and available starting in 1980-1981 (29). Hospital

encounters are recorded in the Danish National Patient Registry (DNPR) (30,31), including data on

medical procedures and discharge diagnoses, coded using the International Classification of Diseases,

8th revision (ICD-8) in 1977-1993 and 10th revision (ICD-10) thereafter (30). Hospital admissions are

available in the DNPR from 1977, while outpatient clinic and emergency room visits are recorded

from 1995 onwards (30,31). Admissions and outpatient specialist visits due to psychiatric conditions

are captured by the Psychiatric Central Research Register (32) and were available from 1995. The

Danish National Prescription Registry (33) captures data on prescribed medication dispensings from

1995 onwards and records the Anatomical Therapeutic Classification (ATC) codes of the dispensed

drugs and the dates when the prescriptions were redeemed. The Danish Cancer Registry (DCR) (34)

captures all primary incident cancer diagnoses and contains data on tumours' morphology.

Study population

Using the MBR, we identified all deliveries between 1995 and 2017. We kept one record per delivery

of a multifetal pregnancy. Using the DNPR, we obtained data on VB within 20 gestational weeks

starting from the last menstrual period date, computed by subtracting gestational age at delivery from

the delivery date. Pregnancies without a VB diagnosis in the DNPR within 20 weeks of gestation and

ending in a delivery were classified as VB-unaffected. The index date for VB-affected and VB-

unaffected pregnancies was the date of delivery.

Using the DNPR, we identified pregnancies ending in a miscarriage (spontaneous abortion) or a

termination (medical or surgical abortion) in 1995-2017, using all recorded diagnoses. To identify

pregnancy terminations, we also used procedure codes from the DNPR (Table 1 in the electronic

supplementary material). To limit the inclusion of multiple records of the same pregnancy registered

in connection with hospital visits due to previous termination, a woman with the same diagnostic or

procedure code for pregnancy termination was allowed to re-enter the cohort after 180 days,

whereupon this was considered a different pregnancy. The same approach using diagnostic codes only

was applied to identify miscarriages. When multiple dates were available for each pregnancy

termination or miscarriage episode, we included the earliest and it served as the index date. Finally,

we excluded pregnancy records of women with pre-existing cancer or HIV/AIDs diagnosis and with

missing age at the index date (Figure 1).

Cancer outcomes

26 Using the DCR, we ascertained incident diagnoses of cancer. We investigated the long-term risk of

27 any cancer; haematological, immune-related, alcohol and smoking-related, obesity-related cancers

28 (35–37) and cancers at multiple specific sites, focusing specifically on breast, cervical, ovarian and

29 fallopian tube, and uterine cancer (Table 1 in the electronic supplementary material).

Covariables

31 The potential confounding factors were age, calendar year of pregnancy end, women's parity,

32 socioeconomic factors (education, employment, and year-specific income level divided into quartiles),

33 reproductive history, chronic somatic and psychiatric conditions (Figure 1 in the electronic

34 supplementary material). We additionally ascertained and adjusted for women's medication use

before the index date as a measure of underlying health and healthcare system utilization beyond

hospital-based contacts. In the comparisons of pregnancies ending in childbirth, we additionally

controlled for placental complications at the index pregnancy as a late manifesting proxy of placental

dysfunction during pregnancy.

Statistical analyses

We followed women from the index date until the earliest of cancer diagnosis, death, emigration, or

end of the study on 31 December 2017. Women with multiple cancers diagnosed at different dates

were followed until the earliest of the cancer diagnoses. we computed the cumulative risk of any

cancer and haematological, immune-related, alcohol and smoking-related, and obesity-related cancers

at the end of a 24-year follow-up while treating deaths and emigrations as competing events. We

computed cumulative incidence at the end of 24-year follow-up with death and emigration as

competing events and incidence rates (IRs) per 10 000 person-years (PYs) of any cancer and breast,

cervical, ovarian and fallopian tube, uterine cancer, and other cancers at specific sites. We used Cox

proportional hazards regression to compute crude and adjusted hazard ratios (HRs) for all investigated

cancer outcomes. We computed 95% confidence intervals (CIs) using a robust standard error when

different pregnancies of the same woman were analysed. In three separate sets of analyses, we

compared the risk of cancer outcomes following a VB-affected pregnancy vs that following VB-

unaffected pregnancy, termination or miscarriage.

For any cancer and haematological, immune-related, alcohol and smoking-related, and obesity-related

cancers, we computed HRs adjusted for potential confounders (women's reproductive history and

placental complications at the current pregnancy ending in delivery; pre-existing thyroid conditions,

obesity, polycystic ovary syndrome, chronic obstructive pulmonary disease, chronic liver and kidney

diseases, medication use as a proxy of women's overall health) using multivariable proportional

hazards Cox regression. Further, we computed the risks of any cancer and cancers at specific sites

following women's first pregnancy. In a sensitivity analysis, we investigated the risk of any cancer

and haematological, immune-related, alcohol or smoking-related, and obesity-related cancers

additionally adjusted for women's BMI in analyses of pregnancies ending in delivery; however, the

follow-up was short and accrued few events. We additionally investigated the risk of cancer

restricting the data to women having their last recorded pregnancy at the age of 40 years or later. We

did not impute missing values and included variables with missing data in the statistical models using

"missing" as a category.

Using log-minus-log plots, we visually evaluated the proportionality of hazards assumptions, and the

curves were close to parallel over the follow-up period. All analyses were conducted at Denmark

Statistics (29) using RStudio (38) and R software for statistical computing (39) versions 3.6.0-4.1.0

including the following packages and their dependencies: tidyverse (40), ggplot2 (41), survival (42),

cmprsk (43), prodlim (44), and epiR (45). Reported counts were clouded to protect personal data.

Ethics

No patient consent or ethical approval is required for registry-based research according to Danish

legislation. This study was reported to the Danish Data Protection Agency (46) through registration at

Aarhus University (record number: AU-2016-051-000001, sequential number 605).

RESULTS

Descriptive characteristics

This study included 37 060 VB-affected pregnancies among 35 495 women; 1 362 785 VB-unaffected

pregnancies among 783 041 women; 324 235 terminations among 239 568 women and 136 975

miscarriages among 121 239 women in 1995-2017 (Figure 1). Women's age, parity, civil status,

employment, income, obesity, chronic pulmonary, chronic liver and kidney conditions, alcohol abuse,

and medication use had similar distributions for VB-affected and VB-unaffected pregnancy cohorts.

Of women with VB-affected vs VB-unaffected pregnancies, 29.0% vs 35.0% had higher education,

13.0% vs 4.9% had a previous record of VB diagnosis irrespective of pregnancy outcome, 6.2% vs

2.1% had a history of a previous VB episode within 20 gestational weeks of a pregnancy ending in a

delivery, 22.0% vs 12.0% had at least one previous miscarriage; 19.0% vs 15.0% were smokers

(Table 1).

Pregnancies ending in termination were more likely to be of younger (<24 years), unmarried,

nulliparous and unemployed women, who had a lower level of the highest attained education and

were in the first income quartile compared with pregnancies ending in a delivery or miscarriage

(Table 1). Pregnancies ending in a miscarriage were more likely than VB-affected pregnancies to be

of women older than 35 years and 15.0% had a previous miscarriage (Table 1).

Cumulative incidences and incidence rates of the cancer outcomes

The median (25th-75th percentile) follow-up was 12.6 (6.9-18.2) years. At the end of the follow-up,

there were 1 710 cancer events following VB-affected pregnancy, 52 625 events following VB-

unaffected pregnancy, 12 925 events following termination and 6 080 events following a miscarriage

(Table 2). At the end of the 24-year follow-up, the cumulative incidence of any cancer was 9.8%

following VB-affected pregnancy and 9.9% following VB-unaffected pregnancy, 9.3% following

termination and 10.3% following a miscarriage (Figure 1 in the electronic supplementary material).

The incidence rate per 10 000 PYs of any cancer was 33.08 (95% CI: 31.54-34.68) for VB-affected

pregnancies and 31.45 (95% CI: 31.18-31.72) for VB-affected pregnancies (Table 2). The incidence

rates per 10 000 PYs of smoking or alcohol-related cancers and obesity-related cancers were slightly

higher following VB-affected (1.68, 95% CI: 1.36-2.06 and 11.68, 95% CI: 10.78-12.64, respectively)

than VB-unaffected pregnancy (1.49, 95% CI: 1.43-1.55 and 11.09, 95% CI: 10.93-11.25,

respectively). The incidence rates of breast, cervical, ovary and fallopian tube, uterine cancer, and

cancers at other sites were similar for all ascertained cohorts (Table 2 and Table 2 in the electronic

supplementary material).

Hazard ratios for the cancer outcomes

The HR for any cancer in the VB-affected pregnancy cohort was 1.02 (95% CI: 0.97-1.07) vs VB-

unaffected pregnancy cohort, 1.05 (95% CI: 1.00-1.11) vs termination cohort, and 0.93 (95% CI:

0.88-0.98) vs miscarriage cohort. In the analyses including the first pregnancy of a woman, the

adjusted models yielded nearly identical results as analyses including all identifiable pregnancies of a

woman (Table 3).

There was no association between VB-affected pregnancy and subsequent risk of haematological,

immune-related, obesity-related or other cancers across all contrasts (Table 3). When investigating the

risk of smoking or alcohol-related cancers following VB-affected vs VB-unaffected pregnancy the

HR was 0.98 (95% CI: 0.79-1.22). We observed 1.5-fold increased hazard of smoking or alcohol-

related cancers following a first identifiable VB-affected vs VB-unaffected pregnancy of a woman

(HR: 1.53, 95% CI: 1.03-2.27) (Table 3). For contrasts of VB-affected pregnancy ending in childbirth

vs pregnancy ending in termination or miscarriage, the HRs for smoking or alcohol-related cancers

were consistent with slightly reduced risk to no association (HR: 0.88, 95% CI: 0.70-1.11 and HR:

0.84, 95% CI: 0.64-1.10, respectively) in analyses of all identifiable pregnancies. The latter

associations could not be adjusted for women's smoking status, since this information was only

available for pregnancies ending in a delivery.

As compared with having VB-unaffected pregnancy, there was no increase in relative risk of breast

(HR: 1.01, 95% CI: 0.92-1.11), cervical (0.95, 0.78-1.16), ovarian and fallopian tube (1.23, 0.86-

1.76), and uterine cancer (0.86, 0.50-1.47) following VB-affected pregnancy (Table 4). Similarly, we

found no association with other investigated site-specific cancers across comparisons with VB-

unaffected pregnancy cohort and cohorts of pregnancies ending in a termination or miscarriage (Table

3 in the electronic supplementary material).

Sensitivity analysis of pregnancies ending in delivery from 2004 onwards with additional adjustment

for woman's BMI in pregnancy showed results generally consistent with the findings from the main

analyses. The HR for smoking or alcohol-related cancers following a first identifiable VB-affected vs

VB-unaffected pregnancy of a woman shifted towards the null value (HR: 0.75, 95% CI: 0.19-3.03);

however, the estimate was based on few cancer events and, thus, was imprecise (Table 4 in the

electronic supplementary material). Some HRs for cancers at specific sites were inestimable due to

short follow-up and few accrued events (Table 5 in the electronic supplementary material). There was

no increased risk of any cancer in analyses of women having their last identifiable pregnancy at the

age of 40 years or later (Table 6 in the electronic supplementary material).

DISCUSSION

Principal findings

In this registry-based cohort study, we found no evidence of an association between VB in pregnancy

carried to delivery and subsequent risk of cancer. When compared with having VB-unaffected

pregnancy, there was no increased risk of any cancer and specifically breast, cervical, ovarian and

fallopian tube, and uterine cancer in women having VB-affected pregnancy. Analysis of a first

identifiable VB-affected vs VB-unaffected pregnancy of a woman showed a 1.5-fold increased hazard

of smoking or alcohol-related cancers; however, this association attenuated towards the null value in a

sensitivity analysis. Similarly, we found no associations with any cancer and site-specific cancers in

women when contrasting having VB-affected pregnancy with termination or miscarriage.

Comparison with other studies

This study is in line with a Danish study reporting no association between VB in pregnancy and occult

cancer (21). The results of this study also indirectly support the findings of previous research showing

that the risk of breast, ovarian and endometrial cancer was similar in women with a gestation history

irrespective of whether the pregnancies were carried until full-term delivery (1,2,19).

Strengths and limitations of the study

Due to nearly complete administrative follow-up for every woman, selection bias at the inclusion of

pregnancies in the study is negligible, but potential selection bias from unidentified early miscarriages

cannot be ruled out. In the analyses, we controlled for multiple potential confounding factors. Data on

proxies of the lifestyle such as smoking and BMI were available only for pregnancies ending in

pregnancies; moreover, data on BMI was only available for a data subset starting from 2004. The 1.5-

fold increased hazard of smoking or alcohol-related cancers in the contrast of a first identifiable VB-

affected vs VB-unaffected pregnancy of a woman can potentially be explained by residual

confounding by lifestyle and BMI. At the same time, no lifestyle factor of women with VB in

pregnancy is likely to dilute the associations and, thus, is unlikely to explain the null associations in

analyses contrasting VB-affected pregnancy ending in delivery with having a termination or

miscarriage.

Diagnosis of VB in pregnancy due to threatened miscarriage was not validated in the DNPR. The

validity of diagnoses for miscarriage and of diagnoses and procedures for pregnancy termination in

the DNPR is high (positive predictive value >90%) (30,47). We could potentially miss recurrent

miscarriages within 180 days of each other. However, owing to high specificity of miscarriage

diagnoses and few false positives, the misclassification of miscarriages is not a major concern. A diagnostic work-up for threatened miscarriage includes an ultrasound for establishing pregnancy viability, foetal heartbeat, and to eliminate other causes of VB such as ectopic pregnancy (8,48). The prevalence of VB in this study is low (<3%) compared with estimates reported elsewhere (up to 30%) (8–12). We argue that identified VB-affected pregnancies in this study had high specificity, however, a large proportion of VB episodes not resulting in a hospital-based encounter were missed. This may cause bias only if captured episodes of VB systematically differ from all such episodes.

Owing to compulsory reporting of incident primary tumours, the accuracy of cancer diagnoses in the DCR and its coverage is very high, with nearly 90% of tumours having a morphological verification (34). Thus, misclassification of the outcome is unlikely in this study and is not expected to explain the null findings. We did not censor women who would no longer be at risk of endometrial, cervical, and uterine cancers due to hysterectomy (49,50) and the risks of these cancer outcomes may be slightly overestimated.

CONCLUSION

We found no evidence of an association between VB in pregnancy and subsequent long-term risk of cancer.

Statements & Declarations

Funding information: The author(s) received no specific funding for this work. Department of

Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from

regulators and pharmaceutical companies, given as research grants to and administered by Aarhus

University. None of these projects is related to the current study.

Author contributions: ED, EHP, HTS, and VE designed the study. HTS facilitated the data

application. ED prepared the statistical analysis plan and conducted statistical analyses. EHP provided

expertise and supervision of the statistical analyses. All authors participated in the discussion of the

results and their interpretation. ED drafted the manuscript, organised the writing, and produced a

graphical presentation of the results. HTS provided clinical expertise. All authors equally participated

in the critical revision of the manuscript and approved its final version. HTS is the guarantor.

Ethics approval and consent to participate: No patient consent or ethical approval is required for

registry-based research according to Danish legislation. This study was reported to the Danish Data

Protection Agency through registration at Aarhus University (record number: AU-2016-051-000001,

sequential number 605).

Consent for publication: Not applicable.

Data availability: The pseudonymised data used in this study are stored on and accessed via the

secure governmental servers of Denmark Statistics (https://www.dst.dk/). According to Danish

legislation, Danish research environments may be granted access to data at an individual level. For

legal reasons and to protect individuals, whose data were analysed, the dataset used in this study will

not be made public.

Competing Interests: None declared.

References:

1. Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide cohort study. BMJ. 2019 Aug 14;366:l4693.

2. Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. Nat Commun. 2018 Oct 23;9(1):4255.

3. Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta. 2014 Apr;35(4):241–8.

4. Calleja-Agius J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and cytokine levels in threatened miscarriage. Gynecol Endocrinol. 2011 Feb;27(2):121–7.

5. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clin Rev Allergy Immunol. 2017 Aug;53(1):40–53.

6. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, et al. Sporadic miscarriage: evidence to provide effective care. The Lancet. 2021 May 1;397(10285):1668–74.

7. Lek SM, Ku CW, Allen JC, Malhotra R, Tan NS, Ostbye T, et al. Validation of serum progesterone <35nmol/L as a predictor of miscarriage among women with threatened miscarriage. BMC Pregnancy Childbirth. 2017 Mar 6;17(1):78.

8. Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1995 Dec 1;63(2):131–4.

9. Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, Mccowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. Acta Obstetricia et Gynecologica Scandinavica. 2012;91(11):1331–8.

10. Strobino B, Pantel-Silverman J. Gestational vaginal bleeding and pregnancy outcome. American Journal of Epidemiology. 1989 Apr 1;129(4):806–15.

11. Wijesiriwardana A, Bhattacharya S, Shetty A, Smith N, Bhattacharya S. Obstetric Outcome in Women With Threatened Miscarriage in the First Trimester. Obstetrics & Gynecology. 2006 Mar;107(3):557–62.

12. Saraswat L, Bhattacharya S, Maheshwari A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. BJOG. 2010 Feb;117(3):245–57.

13. DeVilbiss EA, Naimi AI, Mumford SL, Perkins NJ, Sjaarda LA, Zolton JR, et al. Vaginal bleeding and nausea in early pregnancy as predictors of clinical pregnancy loss. American Journal of Obstetrics and Gynecology. 2020 Oct 1;223(4):570.e1-570.e14.

14. Sapra KJ, Joseph KS, Galea S, Bates LM, Louis GMB, Ananth CV. Signs and Symptoms of Early Pregnancy Loss. Reprod Sci. 2017 Apr;24(4):502–13.

15. Mouri M, Hall H, Rupp TJ. Threatened Abortion [Internet]. 2017 [cited 2021 Apr 6]. Available from: http://europepmc.org/article/NBK/NBK430747

16. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New England Journal of Medicine. 2019 May 9;380(19):1815–24.

17. Ogwulu CO, Goranitis I, Devall AJ, Cheed V, Gallos ID, Middleton LJ, et al. The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2020;127(6):757–67.

18. Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. The Lancet. 2021 May 1;397(10285):1658–67.

19. Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, Brandt PA van den, et al. Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer. 2021;148(9):2068–78.

20. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast cancer research: BCR. 2006;8(4):R43.

21. Dudukina E, Farkas DK, Horváth Puhó E, Prandoni P, Sørensen HT, Ehrenstein V. Vaginal bleeding in early pregnancy and risk of occult cancer. International Journal of Gynecology & Obstetrics. 2019;146(3):387–9.

22. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014 Aug;29(8):541–9.

23. Pedersen CB. The Danish Civil Registration System. Scandinavian Journal of Public Health. 2011;39(7_suppl):22–5.

24. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Danish medical bulletin. 1998 Jun;45(3):320–3.

25. Bliddal M, Broe A, Pottegard A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. Eur J Epidemiol. 2018 Jan;33(1):27–36.

26. Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health. 2011 Jul;39(7 Suppl):91–4.

27. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011 Jul 1;39(7_suppl):95–8.

28. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011 Jul;39(7 Suppl):103–5.

29. Statistics Denmark [Internet]. 2021 [cited 2021 Jun 30]. Available from: https://www.dst.dk/en

30. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.

31. Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. CLEP. 2021 Jul 19;13:533–54.

32. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011 Jul;39(7 Suppl):54–7.

33. Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017 Jun 1;46(3):798–798f.

34. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011 Jul;39(7 Suppl):42–5.

35. Ording AG, Veres K, Farkas DK, Adelborg K, Sorensen HT. Risk of cancer in patients with epistaxis and haemoptysis. Br J Cancer. 2018 Mar 20;118(6):913–9.

36. Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al. Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. Journal of Internal Medicine. 2020;287(4):435–47.

37. Elser H, Skajaa N, Ehrenstein V, Fuglsang CH, Farkas DK, Sørensen HT. Cancer risk in patients with migraine: A population-based cohort study in Denmark. Headache: The Journal of Head and Face Pain. 2022;62(1):57–64.

38. RStudio Team. RStudio: Integrated Development for R [Internet]. Boston, MA: RStudio, PBC; 2020. Available from: http://www.rstudio.com/

39. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria; 2013. Available from: http://www.R-project.org/

40. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the Tidyverse. Journal of Open Source Software. 2019 Nov 21;4(43):1686.

41. Wickham H. ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New York; 2016. Available from: https://ggplot2.tidyverse.org

42. Therneau TM, Thomas L, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2021 [cited 2021 Apr 6]. Available from: https://CRAN.R-project.org/package=survival

43. Gray B. cmprsk: Subdistribution Analysis of Competing Risks [Internet]. 2020 [cited 2021 Mar 31]. Available from: https://CRAN.R-project.org/package=cmprsk

44. Gerds TA. prodlim: Product-Limit Estimation for Censored Event History Analysis [Internet]. 2019 [cited 2021 Mar 31]. Available from: https://CRAN.R-project.org/package=prodlim

45. Nunes MS and ES with contributions from T, Heuer C, Marshall J, Sanchez J, Thornton R, Reiczigel J, et al. epiR: Tools for the Analysis of Epidemiological Data [Internet]. 2021 [cited 2021 Jul 29]. Available from: https://CRAN.R-project.org/package=epiR

46. Datatilsynet. Datatilsynet/The Danish Data Protection Agency [Internet]. Datatilsynet/The Danish Data Protection Agency. [cited 2020 Sep 16]. Available from: http://www.datatilsynet.dk/english

47. Lohse SR, Farkas DK, Lohse N, Skouby SO, Nielsen FE, Lash TL, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol. 2010 Oct 27;2:247–50.

48. Norwitz ER, Park JS, Lockwood CJ, Barss V. Overview of the etiology and evaluation of vaginal bleeding in pregnancy - UpToDate [Internet]. 2021 [cited 2021 Aug 30]. Available from: https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-bleeding-in-pregnancy

49. Gustafson LW, Booth BB, Kahlert J, Ørtoft G, Mejlgaard E, Clarke MA, et al. Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise? International Journal of Cancer. 2021;148(3):584–92.

50. Lycke KD, Kahlert J, Damgaard R, Mogensen O, Hammer A. Trends in Hysterectomy Incidence Rates During 2000-2015 in Denmark: Shifting from Abdominal to Minimally Invasive Surgical Procedures. CLEP. 2021 Jun 1;13:407–16.

Figure 1. Flow chart for the study population ascertainment

Standalone figure

Table 1. Descriptive characteristics of women having a vaginal bleeding-affected, vaginal bleeding-unaffected pregnancy, pregnancy ending in a termination or miscarriage, Denmark, 1995-2017

	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 060	VB-unaffected pregnancy, N = 1 362 785	Termination, N = 324 235	Miscarriage, N = 136 975
Women, N	35 495	783 041	239 568	121 239
Characteristic[a]	n (%)	n (%)	n (%)	n (%)
Age at pregnancy end, years				
<20	565 (1.5)	20 015 (1.5)	46 220 (14.0)	4 635 (3.4)
20-24	5 035 (14.0)	163 915 (12.0)	74 415 (23.0)	17 415 (13.0)
25-29	12 265 (33.0)	464 210 (34.0)	68 095 (21.0)	37 455 (27.0)
30-34	12 370 (33.0)	476 170 (35.0)	65 405 (20.0)	39 800 (29.0)
35-39	5 710 (15.0)	202 305 (15.0)	49 440 (15.0)	26 140 (19.0)
40+	1 125 (3.0)	36 165 (2.7)	20 655 (6.4)	11 530 (8.4)
Calendar year of pregnancy end				
1995-1999	12 660 (34.0)	308 280 (23.0)	88 930 (27.0)	33 550 (24.0)
2000-2004	8 260 (22.0)	243 000 (18.0)	63 405 (20.0)	25 460 (19.0)
2005-2008	7 210 (19.0)	304 210 (22.0)	72 285 (22.0)	33 845 (25.0)
2009-2013	4 730 (13.0)	228 785 (17.0)	50 565 (16.0)	25 330 (18.0)
2013-2017	4 200 (11.0)	278 505 (20.0)	49 045 (15.0)	18 790 (14.0)
Smoking in pregnancy				
Smoker	6 990 (19.0)	209 840 (15.0)	Not available	
Non-smoker	26 185 (71.0)	1 048 845 (77.0)		
Missing	3 885 (10.0)	104 100 (7.6)		
Parity at the index[b]				
Nulliparous	0 (0.0)	0 (0.0)	205 310 (63.0)	110 390 (81.0)
Primiparous	17 090 (46)	628 865 (46.0)	32 745 (10.0)	10 865 (7.9)
Multiparous	19 970 (54.0)	733 920 (54.0)	86 175 (27.0)	15 720 (11.0)
Pregnancy number at the index date				
1	11 290 (30.0)	512 535 (38.0)	112 355 (35.0)	43 980 (32.0)
2	11 535 (31.0)	447 405 (33.0)	59 805 (18.0)	39 910 (29.0)
3+	7 045 (19.0)	232 225 (17.0)	58 790 (18.0)	25 480 (19.0)
Civil status				
Married or in partnership	22 315 (60.0)	832 795 (61.0)	102 425 (32.0)	68 540 (50.0)
Not married	10 525 (28.0)	387 245 (28.0)	165 205 (51.0)	43 060 (31.0)
Missing	4 220 (11.0)	142 745 (10.0)	56 605 (17.0)	25 370 (19.0)
Employment status				
Employed	26 945 (73.0)	1 017 110 (75.0)	194 755 (60.0)	98 570 (72.0)
Retirement or state pension	3 400 (9.2)	100 585 (7.4)	41 220 (13.0)	13 025 (9.5)
Unemployed	5 745 (16.0)	201 395 (15.0)	80 915 (25.0)	21 325 (16.0)
Missing	965 (2.6)	43 690 (3.2)	7 340 (2.3)	4 055 (3.0)
Highest achieved education				
Basic education	9 820 (26.0)	272 035 (20.0)	145 850 (45.0)	35 665 (26.0)
High school or similar	15 085 (41.0)	553 235 (41.0)	109 290 (34.0)	53 355 (39.0)
Higher education	10 585 (29.0)	472 925 (35.0)	48 890 (15.0)	41 065 (30.0)
Missing	1 570 (4.2)	64 585 (4.7)	20 205 (6.2)	6 890 (5.0)
Year-specific income, quartiles				
Q1	8 900 (24.0)	282 180 (21.0)	130 545 (40.0)	33 130 (24.0)
Q2	9 460 (26.0)	326 530 (24.0)	82 275 (25.0)	34 480 (25.0)
Q3	8 875 (24.0)	358 770 (26.0)	52 535 (16.0)	32 670 (24.0)
Q4	9 160 (25.0)	361 670 (27.0)	47 115 (15.0)	33 130 (24.0)
Missing	670 (1.8)	33 630 (2.5)	11 765 (3.6)	3 565 (2.6)
Origin				

Women, N Characteristic[a]	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 060 35 495 n (%)	VB-unaffected pregnancy, N = 1 362 785 783 041 n (%)	Termination, N = 324 235 239 568 n (%)	Miscarriage, N = 136 975 121 239 n (%)
Danish	30 910 (83.0)	1 157 155 (85.0)	273 320 (84.0)	114 620 (84.0)
non-Danish	6 150 (17.0)	205 185 (15.0)	50 910 (16.0)	22 350 (16.0)
Missing	5 (<0.1)	445 (<0.1)		
Reproductive history				
At least one VB diagnosis	4 865 (13.0)	66 290 (4.9)	23 915 (7.4)	16 990 (12.0)
At least one VB diagnosis within 20 gestational weeks of a pregnancy ending in a delivery	2 315 (6.2)	29 280 (2.1)	11 990 (3.7)	5 040 (3.7)
At least one termination	8 610 (23.0)	224 300 (16.0)	110 445 (34.0)	30 170 (22.0)
At least one miscarriage	8 110 (22.0)	165 620 (12.0)	38 615 (12.0)	20 915 (15.0)
Any hypertensive disorder of pregnancy	1 345 (3.6)	45 065 (3.3)	10 910 (3.4)	5 520 (4.0)
Placenta praevia	90 (0.2)	3 465 (0.3)	1 040 (0.3)	470 (0.3)
Abruptio placentae	255 (0.7)	5 995 (0.4)	2 085 (0.6)	930 (0.7)
Gestational diabetes	280 (0.8)	11 015 (0.8)	2 570 (0.8)	1 545 (1.1)
Gestation age of a new-born, weeks (median, 25th-75th percentile)	39.0 (38.0, 40.0)	40.0 (39.0, 41.0)	Not available	
Comorbidities				
Obesity diagnosis	2 480 (6.7)	103 570 (7.6)	11 365 (3.5)	6 135 (4.5)
PCOS	400 (1.1)	12 220 (0.9)	1 150 (0.4)	1 190 (0.9)
Thyroid disorders	915 (2.5)	30 135 (2.2)	5 065 (1.6)	2 945 (2.2)
Rheumatic disorders	25 (<0.1)	630 (<0.1)	150 (<0.1)	75 (<0.1)
COPD	450 (1.2)	14 130 (1.0)	3 410 (1.1)	1 450 (1.1)
Chronic kidney diseases	115 (0.3)	2 745 (0.2)	770 (0.2)	305 (0.2)
Chronic liver diseases	100 (0.3)	3 325 (0.2)	950 (0.3)	385 (0.3)
Cardiovascular diseases or diabetes	1 450 (3.9)	47 510 (3.5)	9 110 (2.8)	5 635 (4.1)
Psychiatric comorbidities				
Schizophrenia	340 (0.9)	8 685 (0.6)	5 735 (1.8)	1 345 (1.0)
Autism spectrum disorders	30 (<0.1)	845 (<0.1)	545 (0.2)	105 (<0.1)
Neurotic disorders	3 660 (9.9)	92 270 (6.8)	42 875 (13.0)	12 035 (8.8)
Eating disorders	480 (1.3)	14 095 (1.0)	5 705 (1.8)	1 650 (1.2)
Personality disorder	1 320 (3.6)	31 330 (2.3)	19 180 (5.9)	4 740 (3.5)
Intellectual disability	30 (<0.1)	815 (<0.1)	655 (0.2)	130 (<0.1)
Behavioural disorder	45 (0.1)	1 290 (<0.1)	975 (0.3)	200 (0.1)
Alcohol abuse history	380 (1.0)	9 675 (0.7)	10 310 (3.2)	1 990 (1.5)
Any psychiatric condition	5 145 (14.0)	140 565 (10.0)	61 985 (19.0)	17 730 (13.0)
Medication use history				
Antipsychotics[c]	995 (2.7)	28 260 (2.1)	14 225 (4.4)	4 355 (3.2)
Mood disorders medication[c]	4 360 (12.0)	139 930 (10.0)	50 345 (16.0)	18 050 (13.0)
Antiepileptics[c]	765 (2.1)	23 620 (1.7)	8 535 (2.6)	3 185 (2.3)
ADHD medication[c]	135 (0.4)	4 810 (0.4)	3 375 (1.0)	645 (0.5)
NSAIDs[c]	18 820 (51.0)	661 255 (49.0)	152 855 (47.0)	71 825 (52.0)
Thyroid disorders medication[c]	675 (1.8)	23 395 (1.7)	4 405 (1.4)	2 745 (2.0)
Steroids for systemic use[c]	2 850 (7.7)	102 310 (7.5)	20 780 (6.4)	11 375 (8.3)
Anti-infectives for systemic use[d]	18,605 (50%)	571,305 (42%)	159,690 (49%)	62,270 (45%)

[a] All counts are clouded according to Denmark Statistics data confidentiality policy

[b] Parity was included in the statistical models as nulli- or primiparous vs multiparous

[c] At least one prescription any time before 12 gestational weeks for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

[d] In the period of 365 days before the index date

	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 060	VB-unaffected pregnancy, N = 1 362 785	Termination, N = 324 235	Miscarriage, N = 136 975
Women, N	35 495	783 041	239 568	121 239
Characteristic[a]	**n (%)**	**n (%)**	**n (%)**	**n (%)**

ADHD, attention-deficit/hyperactivity disorder; COPD, chronic obstructive pulmonary disease; NSAIDs, non-steroid anti-inflammatory disease; PCOS, polycistic ovary syndrome

Table 2. Incidence rates of any cancer, haematological, immune-related, smoking or alcohol-related, and obesity-related cancers following vaginal bleeding-affected pregnancy, vaginal bleeding-unaffected pregnancy, and pregnancy ending in a termination or miscarriage, 1995-2018

	Exposed cohort		Comparator cohorts					
	VB-affected pregnancy, N = 37 060		VB-unaffected pregnancy, N = 1 362 785		Termination, N = 324 235		Miscarriage, N = 136 975	
Women, N	35 495		783 041		239 568		121 239	
	N, events[a]/Incidence Rate, 10 000 PYs (95% CI)							
Any cancer								
All identifiable pregnancies	1 710	33.08 (31.54-34.68)	52 625	31.45 (31.18-31.72)	12 925	30.10 (29.58-30.62)	6 080	34.27 (33.41-35.14)
First identifiable pregnancy	440	29.98 (27.28-32.87)	16 335	27.25 (26.83-27.67)	2 720	19.10 (18.39-19.83)	1 375	26.75 (25.36-28.19)
Haematological cancers								
All identifiable pregnancies	50	0.99 (0.74-1.29)	1 675	1.00 (0.96-1.05)	455	1.06 (0.97-1.16)	235	1.31 (1.15-1.49)
First identifiable pregnancy	10	0.81 (0.44-1.38)	545	0.91 (0.83-0.98)	95	0.68 (0.56-0.83)	50	0.93 (0.70-1.23)
Immune-related cancers								
All identifiable pregnancies	860	16.59 (15.51-17.73)	26 935	16.10 (15.90-16.29)	6 320	14.72 (14.36-15.09)	2 840	16.00 (15.42-16.60)
First identifiable pregnancy	220	14.79 (12.92-16.85)	8 760	14.62 (14.31-14.92)	1 495	10.51 (9.98-11.05)	690	13.42 (12.45-14.45)
Smoking or alcohol-related cancers								
All identifiable pregnancies	85	1.68 (1.36-2.06)	2 490	1.49 (1.43-1.55)	935	2.18 (2.05-2.32)	370	2.07 (1.87-2.30)
First identifiable pregnancy	25	1.76 (1.18-2.54)	600	1.00 (0.92-1.08)	120	0.84 (0.70-1.00)	60	1.21 (0.93-1.54)
Obesity-related cancers								
All identifiable pregnancies	605	11.68 (10.78-12.64)	18 565	11.09 (10.93-11.25)	4 360	10.15 (9.85-10.46)	2 280	12.84 (12.32-13.38)
First identifiable pregnancy	155	10.45 (8.89-12.19)	5 500	9.17 (8.93-9.42)	825	5.79 (5.41-6.20)	490	9.51 (8.70-10.38)
Other cancers								
All identifiable pregnancies	110	2.15 (1.77-2.57)	2 960	1.77 (1.71-1.83)	855	1.99 (1.86-2.12)	360	2.04 (1.83-2.25)
First identifiable pregnancy	30	2.17 (1.51-3.02)	930	1.55 (1.45-1.65)	185	1.29 (1.11-1.48)	85	1.67 (1.35-2.06)
Selected site-specific cancers[b]								
Breast cancer	475	9.18 (8.38-10.04)	14 540	8.70 (8.56-8.84)	3 340	7.80 (7.54-8.07)	1 795	10.14 (9.67-10.61)
Cervical cancer	100	1.98 (1.62-2.39)	3 430	2.05 (1.99-2.12)	955	2.23 (2.09-2.37)	315	1.79 (1.60-2.00)
Ovary and fallopian tube cancer	30	0.62 (0.43-0.86)	760	0.45 (0.42-0.49)	215	0.50 (0.44-0.57)	110	0.62 (0.51-0.75)
Uterine cancer	15	0.27 (0.16-0.44)	495	0.30 (0.27-0.32)	105	0.25 (0.20-0.30)	65	0.37 (0.29-0.47)

[a] All counts are clouded according to Denmark Statistics data confidentiality policy
[b] Computed using all identifiable pregnancies of a woman

Table 3. Hazard ratios with 95% confidence intervals for any cancer, haematological, immune-related, smoking or alcohol-related, and obesity-related cancers 1995-2018

Outcome	Observations	VB-affected vs VB-unaffected pregnancy[a]	VB-affected pregnancy vs termination[b]	VB-affected pregnancy vs miscarriage[b]
		HR (95% CI)		
Any cancer	All identifiable pregnancies	1.02 (0.97-1.07)	1.05 (1.00-1.11)	0.93 (0.88-0.98)
	First pregnancy	1.03 (0.93-1.13)	1.00 (0.90-1.12)	1.09 (0.98-1.22)
Haematological cancers	All identifiable pregnancies	0.94 (0.71-1.24)	0.97 (0.71-1.33)	0.77 (0.54-1.09)
	First pregnancy	0.87 (0.49-1.55)	0.80 (0.41-1.56)	0.92 (0.48-1.77)
Immune-related cancers	All identifiable pregnancies	1.03 (0.96-1.10)	0.96 (0.88-1.03)	1.04 (0.95-1.14)
	First identifiable pregnancy	0.95 (0.83-1.09)	0.93 (0.79-1.09)	1.05 (0.89-1.22)
Smoking or alcohol-related cancers	All identifiable pregnancies	0.98 (0.79-1.22)	0.88 (0.70-1.11)	0.84 (0.64-1.10)
	First identifiable pregnancy	1.53 (1.03-2.27)	1.42 (0.89-2.27)	1.61 (1.00-2.60)
Obesity-related cancers	All identifiable pregnancies	1.01 (0.93-1.09)	1.00 (0.91-1.10)	0.96 (0.87-1.07)
	First identifiable pregnancy	1.04 (0.89-1.23)	1.06 (0.88-1.28)	1.08 (0.90-1.31)
Other cancers	All identifiable pregnancies	1.13 (0.94-1.37)	0.93 (0.75-1.15)	0.96 (0.75-1.24)
	First identifiable pregnancy	1.34 (0.94-1.91)	1.30 (0.85-1.99)	1.34 (0.88-2.04)

[a] Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, smoking, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), chronic somatic and psychiatric conditions, medication use before the index date as a proxy for overall underlying health and healthcare-seeking behaviour

[b] Analyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in termination or miscarriage

Table 4. Hazard ratios with 95% confidence intervals for the risk of breast cancer, cervical cancer, ovarian and fallopian tube cancer, and uterine cancer, 1995-2018

Outcome	Model	VB-affected vs VB-unaffected pregnancy[a,b]	VB-affected pregnancy vs termination[a,c]	VB-affected pregnancy vs miscarriage[a,c]
		HR (95% CI)		
Breast cancer	Crude	1.01 (0.92-1.10)	1.15 (1.05-1.27)	0.87 (0.79-0.96)
	Adjusted	1.01 (0.92-1.11)	1.05 (0.95-1.17)	1.02 (0.91-1.15)
Cervical cancer	Crude	0.96 (0.78-1.16)	0.88 (0.72-1.08)	1.10 (0.88-1.37)
	Adjusted	0.95 (0.78-1.16)	0.82 (0.66-1.02)	1.01 (0.78-1.32)
Ovary and fallopian tube cancer	Crude	1.30 (0.91-1.85)	1.22 (0.84-1.78)	0.95 (0.64-1.42)
	Adjusted	1.23 (0.86-1.76)	0.99 (0.67-1.46)	0.89 (0.56-1.39)
Uterine cancer	Crude	0.86 (0.51-1.46)	1.07 (0.61-1.87)	0.70 (0.40-1.25)
	Adjusted	0.86 (0.50-1.47)	1.06 (0.59-1.89)	0.75 (0.39-1.45)

[a] Computed using all identifiable pregnancies of a woman

[b] Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, smoking, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), chronic somatic and psychiatric conditions, medication use before the index date as a proxy for overall underlying health and healthcare-seeking behaviour

[c] Analyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in termination or miscarriage

Electronic supplementary material

Table 1 Definitions of the exposure, outcomes, and covariables (ICD-8, ICD-10, and ATC codes)

Table 2 Incidence rates for additional investigated cancer sites, 1995-2017

Figure 1 Cumulative incidence of any cancer at the end of 24-year follow-up period following VB-affected, VB-unaffected pregnancy ending in delivery and pregnancy ending in termination or miscarriage, Denmark, 1995-2018

Table 3 Hazard ratios with 95% confidence intervals for additional investigated cancer sites, 1995-2018

Table 4 Hazard ratios with 95% confidence intervals for any cancer and haematological, immune-related, smoking or alcohol-related, and obesity-related cancers after additionally adjusting for smoking in pregnancy, 2004-2018

Table 5 Hazard ratios with 95% confidence intervals for breast, cervical, ovarian and fallopian tube cancers after additionally adjusting for smoking in pregnancy, 2004-2018

Table 6 Hazard ratios with 95% confidence intervals for any cancer following last identifiable pregnancy among women aged 40+ years